RenovoRx Announces Late-Breaking Oral Presentation At 2023 ESMO World Congress On Gastrointestinal Cancer
Portfolio Pulse from Happy Mohamed
RenovoRx (NASDAQ:RNXT) will present new secondary endpoint data from the Phase III TIGeR-PaC study of its lead product candidate RenovoGem at the 2023 ESMO World Congress on Gastrointestinal Cancer. The data includes progression-free survival in the treatment of locally advanced pancreatic cancer.
May 25, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RenovoRx will present new secondary endpoint data from its Phase III TIGeR-PaC study of RenovoGem at the 2023 ESMO World Congress, potentially boosting investor confidence.
The presentation of new secondary endpoint data from the Phase III TIGeR-PaC study of RenovoGem at the 2023 ESMO World Congress could boost investor confidence in RenovoRx's product pipeline and its potential to benefit cancer patients. Positive results may lead to increased interest in the stock and potential upward price movement in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100